PTCHD4

Across TCGA pan-cancer cohorts, PTCHD4 RNA is linked to patient survival in 28 of 34 cancer types, making it the most broadly survival-associated PTCHD4 data layer compared with 6 for mutation status.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher PTCHD4 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated PTCHD4 expression acts as an unfavorable survival marker, although some lineages such as KIRP and KIRC show a favorable association.

STAD, KIRP, and KIRC are the cancer types where PTCHD4 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.314	0.512	<.001	94	view →
KIRP	DFS	Quartile	All	0.910	0.706	<.001	93	view →
KIRC	OS	Median	All	0.920	0.838	.003	77	view →
BLCA	OS	Median	IV	0.343	0.583	<.001	56	view →
LIHC	OS	Median	II,III,IV	0.558	0.295	<.001	50	view →
SCLC	DFS	Median	III,IV	0.538	0.232	.005	28	view →
CHOL	OS	Median	All	0.349	0.733	.008	26	view →
ACC	OS	Tertile	II,III,IV	0.768	0.380	.009	25	view →
HNSC	DFS	Quartile	All	0.650	0.771	.017	20	view →
UCEC	DFS	Quartile	II,III,IV	0.918	0.735	.001	18	view →
KICH	OS	Quartile	III,IV	1.000	0.368	.011	16	view →
BRCA	OS	Tertile	All	0.454	0.662	.004	16	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 28 lineages.

PTCHD4–STAD (OS)

Open the STAD breakdown →